Storage Drop Storage Technologies Ltd.

Investor Presentation • Jun 2, 2020

Disclaimer

This presentation was conducted for the purpose of extract and convenience only and is not intended to replace the need to review the immediate reports published by .the Company to the public

Full and comprehensive information about the Company and its business can be found in the annual and immediate reports published by the Company on the Israel .Securities Authority's website at - www.magna.isa.gov.il

The forecasts in this presentation are based on data, information and assessments held by the Company at the time of the presentation, and the Company does not undertake to update and / or change the forecasts and / or assessments as such, to reflect events and / or circumstances that will apply after this presentation date. This presentation may include data and information that are not included in the Company's annual and / or immediate reports as published to the public or whose presentation in this presentation is different from the manner included in the Company's published reports. In the event of a conflict between reports published to the .public and the data in this presentation, only the data published by the Company in its immediate reports should be considered by virtue of the legal requirements In this presentation, the Company included, in relation to itself and in relation to investees or affiliates, forward-looking information, as defined in the Securities Law, 1968. Such information includes, among other things, forecasts, objectives, estimates, and other information relating to any events or matters, whose materialization is uncertain and may be influenced by factors that cannot be assessed in advance and which are outside the Company's control, including technological and engineering difficulties, weather, natural and pest damage, regulatory changes, difficulties or delays related to research grants, the scope of future funding sources, and the ability to mobilize such sources, changes in work plans, failure to obtain relevant health authority approvals at the expected date, changes in technologies, changes in target markets, decisions of portfolio companies not to continue product development in the format prescribed for each of the aforementioned factors and / or the risk factors that characterize the Company's activities. The Company's forward-looking information is based on the Company's management estimates, which are based, inter alia, on information known to the Company's management at the time of the presentation, including assessments of the Company's business markets, data, statistics and publications published by various entities and authorities, the contents of which have not been independently audited by the Company and therefore the Company is not .responsible for their correctness

The realization of the forward-looking information, in whole or in part, or in a different way than expected, or its non-realization, will be influenced, inter alia, by the risk factors that characterize the Company's operations as well as developments in the economic environment and external factors affecting the Company in its areas of activity. The Company does not guarantee that its assessments, plans and expectations will be realized and therefore the results of its operations may differ materially from .the results estimated or implied by this information

.The presentation does not constitute an invitation or offer to purchase the Company's securities

Mission Statement

Our Mission is to provide people all over the world with high-quality, research-based organic medical cannabis products, taking advantage of the unique benefits of the Arava region.

Our Leading Team

Dr. Sharon Rozenblat, Ph.D. CTO Hava R&D

Consultant in the field of herbal research and product development for the cosmetics, pharmaceutical and raw materials industries. Has over 15 years experience in the Israeli Biotech industry in R&D management positions, mainly in the field of dermatology.

Farm owner – 9 years' experience in agricultural systems management. Former VP at the Bein Hashitin Association. Holds a BA in behavioral sciences from

Ben Gurion University.

Dana Meltzer CEO and Co-Founder-Co

Farm owner- 18 years' experience in agricultural management and export. Registered nurse. Holds a BSN from the Hebrew University.

David Grossman Partner and Strategic Consultant

Over 17 years experience in VC, PE, and management of publicly traded companies, mainly Healthcare. BA in Business Administration from the Interdisciplinary Center - Herzliya.

Roni Schor CTO Hava Arava

Over 20 experience of growing and extraction. Inventor of 7 medical device related patents. Breeding collaboration with cannabis seed banks

Dror Meltzer COO

Electrical Engineer and an organic vegetables farmer for export. Over 16 years' experience in agronomic operations management.

Experienced CFO with a demonstrated history of working in technology start-up and industrial/manufacturing companies. Experienced in both public and private companies, M&A - sell and buy-side, hundreds of millions of US\$ raise of equity and debt from venture capital firms, strategic and private investors. Leadership of all financial and operational activities in the company

Market Size Cannabis General*

Hava Cannabis Arava When Pressure is Positive

Initial approval for propagation and cultivation processing research and development.

Unique genetics

Cultivation using advanced technologies - Using positive pressure and natural sunlight to cultivate premium quality with an energy efficient method

Scope of up to 25 acres and significant expansion possibilities.

Interdisciplinary and experienced team

Arava Region Between the Red Sea and the Dead Sea

• Hava is located at the Arava Region, an arid desert in the south of Israel enjoying 320 sunny days a year!
• Mild dry winter steady high radiation
• Israel's most productive and advanced agricultural region.
• Largest fresh produce exporter in Israel
• Government support
• R&D center for both agronomical and scientific research located in the Arava – sponsored by the government and provides services to the local farmers and technological innovations.
• Favorable terms of radiation and humidity for cannabis cultivation.

Hava Cannabis Arava

Advantages

Revolutionary Technology

Unique Genetics

Natural Sunlight

Energy Efficient (up to 75% less energy then indoor growing)

Radiation Free

Research Based products

Experienced Multidisciplinary team

Medical Cannabis Go To Market Strategy Cultivating

Initial Target Territories: Israel, Germany. Europe and other legal jurisdictions thereafter

GAP, GACP certified premium, high THC cannabis inflorescence

Post Harvest GMP certified.

Manufacturing

Agreements with potential partners for selling of raw material of final products (in negotiation)

Branding and PR

building Hava's brand through the medical community, social media, PR etc.

Distribution & selling)

Agreements with local distributors and channels, e.g. pharmacies (in negotiation)

Current retail Price Dried packed high-quality inflorescence: .

Germany \$21 per Gram Israel \$8 per Gram

Hava Arava R&D

Hava Arava – R&D In a nutshell

Development of research-based topical products containing cannabinoids (hempderived) and unique local herbal extracts

Research approved by Ministry of Health

Israel Innovation Authority approved grant of 75% of NIS 880K (May 2020)

Unique formulations based on a synergetic effects between cannabinoids and herbal extracts - IP in progress

Research at Israel's most advanced dermatology labs

Experienced team

Distribution agreement with a major player in the EU (in negotiation)

Livni Gilad :Photo צילם: גלעד לבני Development according to markets regulation: 1) US - under OTC Monograph regulation and 2) EU - under the Cosmetic regulation

Hava Arava - Our Brand

Hava Arava – R&D Background

• Eczema is a name for a group of skin conditions characterized in a rash, dry and red skin, and itching, it is known to diminish significantly the well being of the patients.
• Most common kind of Eczema is Atopic dermatitis
• 20% children and 10% adults in developed countries suffer from Eczema
• 30 million Americans suffer from Eczema
• Today there is no safe and efficacious treatment for ongoing long-term use

Hava Arava – R&D Products & Current Status

Our products:

Topical treatment based on a synergy of hemp derived cannabinoids and herbal extracts

Innovative multi -targeted solution:

• anti inflammatory
• anti microbially (S.aureus )
• reduces itch
• restores skin barrier

Current Status:

Lab work and testing for the past few months. Start operating under the grant of the Israel Innovation Authority (June 2020).

Estimated Timeline

"Only those who will risk going too far, can possibly find out how far one can go"

Albert Einstein